Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.
Curr Protoc. 2023 Oct;3(10):e897. doi: 10.1002/cpz1.897.
Trogocytosis is a process in which receptors on acceptor cells remove and internalize cognate ligands from donor cells. Trogocytosis has a profound and negative impact on mAb-based cancer immunotherapy, as seen in the treatment of chronic lymphocytic leukemia (CLL) with CD20 mAbs, such as rituximab (RTX) and ofatumumab (OFA). Our clinical observations of RTX/OFA-mediated loss of the CD20 target from circulating CLL cells have been replicated in our in vitro studies. Here we describe flow cytometry and fluorescence microscopy experiments, which demonstrate that acceptor cells, such as monocytes/macrophages that express FcγR, remove and internalize both antigen and donor cell-bound cognate IgG mAbs for several different mAb-donor cell pairs. Fluorescent mAbs and portions of the plasma cell membrane are transferred from donor cells to acceptor cells, which include the THP-1 monocytic cell line as well as freshly isolated monocytes. We describe rigorous controls to validate the reactions and eliminate dissociation or internalization as alternative mechanisms. Trogocytosis is likely to contribute to neutropenia, thrombocytopenia, and liver damage associated with use of antibody-drug conjugates. The methods we have described should allow for examination of strategies focused on blocking trogocytosis and its adverse effects. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Trogocytosis of mAb-opsonized donor cells mediated by adherent THP-1 cells Alternate Protocol: Application of fluorescence microscopy to examine THP-1 cell-mediated trogocytosis Support Protocol 1: Alexa labeling of mAbs and determination of F/P ratios Support Protocol 2: Standard washing procedure Support Protocol 3: Labeling and opsonization of cells Basic Protocol 2: Trogocytosis mediated by human monocytes as acceptor cells Support Protocol 4: Isolation of human monocytes Basic Protocol 3: Trogocytosis mediated by THP-1 cells in solution Support Protocol 5: Retinoic acid treatment of THP-1 cells Support Protocol 6: Culturing of SCC-25, BT-474, MOLT-4 and THP-1 cell lines.
细胞融合是一种受体在受容细胞中移除并内化同源配体的过程。细胞融合对基于单抗的癌症免疫疗法有深远的负面影响,在慢性淋巴细胞白血病 (CLL) 的治疗中可见,例如使用 CD20 单抗,如利妥昔单抗 (RTX) 和奥法木单抗 (OFA)。我们在体外研究中复制了我们对 RTX/OFA 介导的循环 CLL 细胞中 CD20 靶标丢失的临床观察。在这里,我们描述了流式细胞术和荧光显微镜实验,这些实验表明,表达 FcγR 的受容细胞,如单核细胞/巨噬细胞,会移除并内化几种不同的单抗-供体细胞对的抗原和供体细胞结合的同源 IgG 单抗。荧光单抗和浆细胞膜的一部分从供体细胞转移到受体细胞,包括 THP-1 单核细胞系和新鲜分离的单核细胞。我们描述了严格的对照来验证反应,并排除解离或内化作为替代机制。细胞融合可能导致与抗体药物偶联物使用相关的中性粒细胞减少症、血小板减少症和肝损伤。我们描述的方法应该允许检查专注于阻断细胞融合及其不良影响的策略。© 2023 作者。Wiley Periodicals LLC 出版的当前方案。基础方案 1:通过贴壁 THP-1 细胞介导的单抗调理供体细胞的细胞融合 可选方案 1:应用荧光显微镜检查 THP-1 细胞介导的细胞融合 支持方案 1:mAb 的 Alexa 标记和 F/P 比值的测定 支持方案 2:标准洗涤程序 支持方案 3:细胞的标记和调理 基础方案 2:作为受容细胞的人单核细胞介导的细胞融合 支持方案 4:人单核细胞的分离 基础方案 3:在溶液中由 THP-1 细胞介导的细胞融合 支持方案 5:THP-1 细胞的维 A 酸处理 支持方案 6:SCC-25、BT-474、MOLT-4 和 THP-1 细胞系的培养。